Table of Contents
About This Report Beginning with the recent approval of Gilenya (Novartis; fingolimod), MS patients are experiencing the arrival of more effective and less invasive treatment options after numerous years of limited therapeutic options. As competition intensifies, the need for less invasive modes of administration will be met and new drugs will have to compete on other factors, such as efficacy. What's Included in This Rep...More »
The Largest Collection of Market Research Reports
From +200,000 authoritative sources
Talk to Amrita
+1 718 303 2019
PharmaPoint: Microvascular Complications of Diabetes - Global Drug Forecast and Market Analysis to 2022 Summary The entire market for microvascular complications of diabetes (MCD) - diabetic nephropathy, ...
PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked ...
Product Synopsis Disease-related, demographic, and desire-led drivers are making health of growing importance to food marketers. However, barriers such as cost, habits, and confusion over how to eat healthily ...
... New congenital heart disease review what matters a commitment to research ensures that services are continually focussed on improvement and development, so networks will be required to have ...
... Conditions back pain musculoskeletal injuries stress minor illnesses the most common causes of short-term absence in non-manual workers (%) source bupa jan 2013 absence statistics 0 20 40 60 80 100 ...
Reportlinker.com © Copyright 2014. All rights reserved.